摘要
目的:观察复方中药益肾达络饮治疗实验性自身免疫性脑脊髓炎(EAE)的疗效,研究益肾达络饮对EAE小鼠脊髓中CXCL12和CXCR4因子的影响,并探讨益肾达络饮治疗EAE的作用机制。方法:80只小鼠随机分为正常组、模型组、激素组和益肾达络饮组,造模后给予相应药物。使用HE染色观察EAE小鼠病理特征,采用免疫组织化学法和Western blot测定EAE小鼠脊髓中CXCL12、CXCR4信号表达的变化。结果:与模型组比较,益肾达络饮组能抑制EAE小鼠体质量的降低(P<0.05),改善EAE小鼠脊髓的炎性浸润(P<0.05);与正常组比较,模型组CXCL12、CXCR4表达水平显著升高(P<0.05);与模型组比较,两治疗组CXCL12、CXCR4表达水平显著降低(P<0.01,P<0.05)。结论:益肾达络饮能有效抑制EAE小鼠体质量降低、改善EAE小鼠脊髓的炎性浸润,这种作用与其抑制CXCL12、CXCR4因子的表达有关。
Objective: To observe the therapeutic effect of compound Chinese medicine Yishen Daluo Decoction in the treatment of experimental autoimmune encephalomyelitis(EAE), to study the effects of Yishen Daluo Decoction on CXCL12 and CXCR4 factors in spinal cord of EAE mice and the mechanism of Yishen Daluo Decoction in the treatment of EAE. Methods:A total of 80 mice were randomly divided into normal control group, model group, hormone group and Yishen Daluo Decoction group, and the corresponding drugs were given after the models were established. The pathological characteristics of EAE mice were observed by HE staining. The expression of CXCL12/CXCR4 signal in spinal cord of EAE mice was determined by immunohistochemistry and Western blot. Results: Yishen Daluo Decoction can inhibit the weight loss of EAE mice(P<0.05),and improve the inflammatory infiltration of spinal cord in EAE mice(P<0.05). Compared with the normal control group, the expression level of CXCL12 and CXCR4 in the model group was increased(P<0.05). Compared with the model group, the expression level of CXCL12 and CXCR4 in the two treatment groups was decreased(P<0.01, P<0.05). Conclusion: Yishen Daluo Decoction can effectively inhibit the weight loss of EAE mice and improve the inflammatory infiltration of spinal cord in EAE mice. The effects may be related to the inhibition of the expression of CXCL12 and CXCR4 factor.
引文
[1]Calabres M,Favaretto A,Martini V,et al.Grey matter lesions in MS from histology to clinical implications.Prion,2013,7(1):20-27
[2]Matsushita T.Multiple sclerosis:current therapies and future perspectives.Nihon Rinsho,2011,69(11):2077-2086
[3]Holman D W,Klein R S,Ransohoff R M.The blood-brain barrier,chemokines and multiple sclerosis.Biochim Bio Phys Acta,2011,1812:220-230
[4]Soelberg Sorensen P.Safety concerns and risk management of multiple sclerosis therapies.Acta Neurologica Scandinavica,2016,136(3):168-186
[5]尚晓玲,高颖.关于多发性硬化病因病机的理论探讨.中国中医基础医学杂志,2006,12(6):414
[6]朱文浩,高颖,刘璐.益肾达络饮对实验性自身免疫性脑脊髓炎小鼠细胞外信号调剂激酶1/2通路的影响.中华中医药杂志,2016,31(2):704-707
[7]关东升,高颖.益肾达络饮对实验性自身免疫性脑脊髓炎TNF-α的影响.中国实验方剂学杂志,2013,19(17):279-282
[8]关东升,高颖,娄丽霞,等.益肾达络饮对实验性自身免疫性脑脊髓炎NF-κB信号传导通路的影响.中国中医基础医学杂志,2012,18(7):732-735
[9]尚晓玲,高颖,尹岭,等.益肾达络饮对实验性自身免疫性脑脊髓炎MCP-1的影响.天津中医药,2006,23(5):405-408
[10]申玉娟.益肾达络饮加减治疗复发-缓解型多发性硬化缓解期临床疗效观察.北京:北京中医药大学,2015
[11]Noroozi Karimabad M,Khanamani Falahati-Pour S,Hassanshahi G.Significant role(s)of CXCL12 and the SDF-13:A genetic variant in the pathogenesis of multiple sclerosis.Neuroimmunomodulation,2016,23(4):197-208
[12]杨志峰,杨清玲,陈昌杰.趋化因子SDF-1与受体CXCR4的研究进展.分子诊断与治疗杂志,2011,3(1):58-60
[13]张健,曾育琦,张静,等.实验性自身免疫性脑脊髓炎鼠模型建立及其病理特点.福建医科大学学报,2015,49(1):16-19